स्तनाचा कर्करोग (ब्रेस्ट कॅन्सर)
A phase 3 clinical study conducted across multiple sites, an unpremeditated, unmasked trial, standard of care, side-by-side comparison study of Pyrotinib plus Capecitabine compared with Lapatinib plus Capecitabine in patients with HER2-positive advanced breast cancer.
हॉस्पिटलशी संपर्क साधा
रजिस्ट्रीमध्ये या हॉस्पिटलला ट्रायलचा मुख्य संपर्क म्हणून दिलं आहे. कोणते हॉस्पिटल्स रुग्ण घेत आहेत, हे त्यांना विचारा.
रजिस्ट्री सारांश (तांत्रिक)
A phase III, multicentre, randomized, open label, active controlled, parallel group, non-inferiority study of Pyrotinib plus Capecitabine compared with Lapatinib plus Capecitabine in patients with HER2-positive metastatic breast cancer - Nil
Sponsor: Syngene International Limited
CTRI वर CTRI/2025/09/094678, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 14 Sep 2026 · read by us 5 Nov 2026